Antibacterial medicines - discover performance and commercial prospects of companies


How are leading companies in the antibacterial drugs market performing? Visiongain's new report gives you data, analyses and revenue predictions for antibacterial manufacturers.

See how top companies worldwide are performing and where they are heading. You assess their technologies, products and commercial prospects to 2022.

In our study you find analytical profiles for leading antibiotics producers. The work shows product ranges, R&D and sales prospects, with revenue forecasts from 2012 to 2022:
• Pfizer
• GSK
• Merck & Co.
• Novartis
• Bayer
• J&J
• Cubist Pharmaceuticals
• AstraZeneca
• Abbott Laboratories
• Medicis
• Coverage of 10 other leading manufacturers and four top emerging companies.

You see how antibacterial drug producers compare, discovering how they can compete from 2012. You also find out what will stimulate and restrain business for companies.

The report covers leading pharmaceutical players, specialty companies and emerging organisations. Also, you find companies grouped by region of origin:
• The US
• Europe
• Japan.

Our investigation gives you business research and analysis, including revenue forecasts at world market, submarket and company level to 2022. You find commercial data, predictions, and analyses for leading organisations, their industry and their market area.


Antibacterial drug producers: commercial outlook from 2012


Where is the antibiotics market heading? Many opportunities exist in that industry and market, particularly with the development of new classes of antibacterial drug. In particular, treatments targeting C. difficile and MRSA infections will make a difference to 2022.

Patent expiries will challenge antibiotic manufacturers throughout this decade, with generic pharmaceutical sales prominent and growing. Companies will use product lifecycle management to reduce declines of brands and stimulate their sales, our analysis shows.

What about product launches, new drug classes and expanded indications? The antibacterial R&D pipeline has limitations but holds promise. You find out how leading companies can contribute to our predicted growth and renewal of the market to 2022.

In 2012, more than 50 product candidates are in clinical trials. There are many opportunities for collaborations and in-licensing. Many under-met treatment needs exist.

Which companies are best placed to harness opportunities in the discovery, development, manufacturing and marketing of antibacterial medicines? Our study shows you and explains.


Company analyses, revenue forecasts, R&D and discussions of industry prospects


In visiongain's report you find historical revenues, sales predictions, growth rates and market breakdowns. Also, you see discussions of companies, product portfolios, R&D, commercial news and revenue potentials. You receive 95 tables and 66 charts.


Ten ways Top 20 Antibacterial Drug Manufacturers 2012-2022 helps you


In particular, our study gives you the following knowledge on the topic:
• Assess 20 leading antibacterial drug manufacturers, discovering their activities and outlooks from 2012
• Discover overall world market and submarket revenue forecasts to 2022
• Receive analyses of leading companies, seeing revenue forecasts to 2022
• View a comparative analysis of trends among antibacterial manufacturers
• Find existing revenues and operational data for leading companies
• Review pipeline developments, assessing R&D trends and potential
• Analyse recent licensing deals and acquisitions
• Investigate competition and opportunities influencing sales
• Review prospects for emerging companies and antimicrobial specialists
• Find out what will stimulate and restrain the industry and

Table Of Contents


Table of Contents

1. Executive Summary
1.1 Leading Antibacterial Drug Manufacturers: Overview of Findings
1.2 Chapter Breakdown
1.3 Research and Analysis Methods
1.4 Scope of this Report
1.4.1 Drugs Considered for this Report
1.4.1.1 Ophthalmic and Dermatologic Antibacterials
1.4.2 The Chinese Antibacterial Drugs Market
1.5 Terminology Used in this Report

2. An Introduction to the Antibacterial Drugs Market
2.1 Bacterial Infections and Antibacterial Drugs
2.1.1 Gram-Positive and Gram-Negative Infections
2.1.2 Treating Bacterial Infections
2.2 The Antibacterial Drugs Market 2011
2.2.1 Leading Classes of Antibacterial Drug
2.2.1.1 Cephalosporins
2.2.1.2 Penicillins
2.2.1.3 Fluoroquinolones
2.2.1.4 Macrolides
2.2.1.5 Carbapenems
2.3 The Antibacterial Drugs Market: Overall Revenue Forecast 2012-2022
2.3.1 Market Drivers 2012-2022
2.3.2 Market Restraints 2012-2022
2.4 Leading Antibacterial Drug Manufacturers in 2011
2.4.1 Company Comparison
2.4.1.1 Broad Product Portfolios
2.4.1.2 Regional Focus
2.4.1.3 Future of the Antibacterial Drugs Industry

3. The Leading US Big Pharma Antibacterial Drug Manufacturers 2012-2022
3.1 Pfizer
3.1.1 A Long History in Antibacterials
3.1.2 Antibacterial Product Portfolio
3.1.2.1 Dalacin (Clindamycin)
3.1.2.2 Sulperazon (Cefoperazone/Sulbactam)
3.1.2.3 Tygacil (Tigecycline)
3.1.2.4 Unasyn (Ampicillin/Sulbactam)
3.1.2.5 Zithromax (Azithromycin)
3.1.2.6 Zosyn (Piperacillin/Tazobactam)
3.1.2.7 Zyvox (Linezolid)
3.1.3 Antibacterial Revenue 2011
3.1.4 Pipeline
3.1.4.1 Pipeline 2007-2010
3.1.4.2 PNU-100480 (Sutezolid)
3.1.5 Pfizer Antibacterials: SWOT Analysis
3.1.6 Antibacterial Revenue Forecast 2012-2022
3.2 Merck and Co.
3.2.1 Antibacterial Product Portfolio
3.2.1.1 Avelox (Moxifloxacin)
3.2.1.2 Invanz (Ertapenem)
3.2.1.3 Primaxin (Imipenem/Cilastatin)
3.2.2 Antibacterial Revenue 2011
3.2.3 Recent Licensing Deals
3.2.4 Pipeline
3.2.4.1 MK-3415A
3.2.4.2 MK-7655
3.2.5 Merck Antibacterials: SWOT Analysis
3.2.6 Antibacterial Revenue Forecast 2012-2022
3.3 JandJ
3.3.1 Antibacterial Product Portfolio
3.3.1.1 Doribax (Doripenem)
3.3.1.2 Levaquin (Levofloxacin)
3.3.2 Antibacterial Revenue 2011
3.3.2.1 Patent Challenges
3.3.3 Decreasing Investment in Antibacterials
3.3.4 Pipeline: TMC207
3.3.5 JandJ Antibacterials: SWOT Analysis
3.3.6 Antibacterial Revenue Forecast 2012-2022
3.4 Abbott Laboratories
3.4.1 Antibacterial Product Portfolio
3.4.1.1 Biaxin (Clarithromycin)
3.4.2 Antibacterial Revenue 2011
3.4.3 Abbott Antibacterials: SWOT Analysis
3.4.4 Antibacterial Revenue Forecast 2012-2022

4. The Leading European Big Pharma Antibacterial Drug Manufacturers 2012-2022
4.1 GSK
4.1.1 Antibacterial Product Portfolio
4.1.1.1 Augmentin (Amoxicillin/Clavulanate)
4.1.1.2 Bactroban (Mupirocin)
4.1.1.3 Duac (Clindamycin/Benzoyl Peroxide)
4.1.1.4 Fortum (Ceftazidime)
4.1.1.5 Zinnat (Cefuroxime)
4.1.2 Antibacterial Revenue 2011
4.1.3 Antibacterials in the US
4.1.4 Pipeline
4.1.4.1 GSK2251052
4.1.4.2 GSK1322322
4.1.5 GSK Antibacterials: SWOT Analysis
4.1.6 Antibacterial Revenue Forecast 2012-2022
4.2 Novartis
4.2.1 Antibacterial Product Portfolio
4.2.1.1 Ciprodex (Ciprofloxacin/Dexamethasone)
4.2.1.2 Cubicin (Daptomycin)
4.2.1.3 Moxeza (Moxifloxacin)
4.2.1.4 TOBI Podhaler (Tobramycin Inhalation Powder)
4.2.1.5 Vigamox (Moxifloxacin)
4.2.2 Antibacterial Revenue 2011
4.2.3 Entering and Exiting Licensing Agreements
4.2.4 Pipeline
4.2.4.1 Finafloxacin
4.2.4.2 LFF571
4.2.5 Novartis Antibacterials: SWOT Analysis
4.2.6 Antibacterial Revenue Forecast 2012-2022
4.3 Bayer
4.3.1 Antibacterial Product Portfolio
4.3.1.1 Avelox (Moxifloxacin)
4.3.1.2 Cipro (Ciprofloxacin)
4.3.2 Antibacterial Revenue 2011

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.